Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20⁺ B-cell lymphoma

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56(2), 185–229 (2004).
  Medline CASGoogle Scholar
• 2 Van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 6, CD003917 (2011).•• Regularly updated epidemiological meta-analyses of cardioprotective interventions against anthracycline-induced cardiotoxicity (ACT).
  MedlineGoogle Scholar
• 3 Lyu YL, Kerrigan JE, Lin CP et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 67(18), 8839–8846 (2007).• First evidence for an oxidative stress-independent component in ACT pathophysiology.
  Medline CASGoogle Scholar
• 4 Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin. Oncol. 25(4 Suppl. 10), 72–85 (1998).
  Medline CASGoogle Scholar
• 5 Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112(12), 2789–2795 (2008).• First report of a genetic component in ACT in survivors of childhood cancers.
  MedlineGoogle Scholar
• 6 Blanco JG, Sun CL, Landier W et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes – a report from the Children's Oncology Group. J. Clin. Oncol. 30(13), 1415–1421 (2012).
  Medline CASGoogle Scholar
• 7 Visscher H, Ross CJ, Rassekh SR et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J. Clin. Oncol. 30(13), 1422–1428 (2012).•• An ACT-predisposing gene variant found in three different cohorts of survivors of childhood cancers.
  MedlineGoogle Scholar
• 8 Visscher H, Ross CJ, Rassekh SR et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr. Blood Cancer 60(8), 1375–1381 (2013).
  Medline CASGoogle Scholar
• 9 Lipshultz SE, Lipsitz SR, Kutok JL et al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer 119(19), 3555–3562 (2013).
  Medline CASGoogle Scholar
• 10 Wang X, Liu W, Sun CL et al. Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group. J. Clin. Oncol. 32(7), 647–653 (2014).
  Medline CASGoogle Scholar
• 11 Windsor RE, Strauss SJ, Kallis C, Wood NE, Whelan JS. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer 118(7), 1856–1867 (2012).
  Medline CASGoogle Scholar
• 12 Wojnowski L, Kulle B, Schirmer M et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112(24), 3754–3762 (2005).• First report of a genetic component in ACT.
  Medline CASGoogle Scholar
• 13 Rossi D, Rasi S, Franceschetti S et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 23(6), 1118–1126 (2009).
  Medline CASGoogle Scholar
• 14 Armenian SH, Ding Y, Mills G et al. Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br. J. Haematol 163(2), 205–213 (2013).
  Medline CASGoogle Scholar
• 15 Cascales A, Pastor-Quirante F, Sanchez-Vega B et al. Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms. Oncologist 18(4), 446–453 (2013).
  Medline CASGoogle Scholar
• 16 Deng S, Kruger A, Kleschyov AL, Kalinowski L, Daiber A, Wojnowski L. Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH. Free Radic. Biol. Med. 42(4), 466–473 (2007).
  Medline CASGoogle Scholar
• 17 Zhao Y, Mclaughlin D, Robinson E et al. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy. Cancer Res. 70(22), 9287–9297 (2010).
  Medline CASGoogle Scholar
• 18 Meier Y, Pauli-Magnus C, Zanger UM et al. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 44(1), 62–74 (2006).
  Medline CASGoogle Scholar
• 19 Pfreundschuh M, Schubert J, Ziepert M et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20⁺ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 9(2), 105–116 (2008).
  Medline CASGoogle Scholar
• 20 Jungsuwadee P, Zhao T, Stolarczyk EI et al. The G671V variant of MRP1/ABCC1 links doxorubicin-induced acute cardiac toxicity to disposition of the glutathione conjugate of 4-hydroxy-2-trans-nonenal. Pharmacogenet. Genomics 22(4), 273–284 (2012).
  Medline CASGoogle Scholar
• 21 Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy–Weinberg equilibrium. Am. J. Hum. Genet. 76(5), 887–893 (2005).
  Medline CASGoogle Scholar
• 22 Cooper H, Hedges LV. The Handbook of Research Synthesis. Russel Sage Foundation, Newbury Park, CA, USA (1994).
  Google Scholar
• 23 Nsengimana J, Bishop DT. Design considerations for genetic linkage and association studies. Methods Mol. Biol. 850, 237–262 (2012).
  MedlineGoogle Scholar
• 24 Lipshultz SE, Lipsitz SR, Sallan SE et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J. Clin. Oncol. 23(12), 2629–2636 (2005).
  Medline CASGoogle Scholar
• 25 Shalom-Barak T, Knaus UG. A p21-activated kinase-controlled metabolic switch up-regulates phagocyte NADPH oxidase. J. Biol. Chem. 277(43), 40659–40665 (2002).
  Medline CASGoogle Scholar
• 26 Price MO, Atkinson SJ, Knaus UG, Dinauer MC. Rac activation induces NADPH oxidase activity in transgenic COSphox cells, and the level of superoxide production is exchange factor-dependent. J. Biol. Chem. 277(21), 19220–19228 (2002).
  Medline CASGoogle Scholar
• 27 Schirmer M, Hoffmann M, Kaya E, Tzvetkov M, Brockmoller J. Genetic polymorphisms of NAD(P)H oxidase: variation in subunit expression and enzyme activity. Pharmacogenomics J. 8(4), 297–304 (2008).
  Medline CASGoogle Scholar
• 28 Inoue N, Kawashima S, Kanazawa K, Yamada S, Akita H, Yokoyama M. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation 97(2), 135–137 (1998).
  Medline CASGoogle Scholar
• 29 Wyche KE, Wang SS, Griendling KK et al. C242T CYBA polymorphism of the NADPH oxidase is associated with reduced respiratory burst in human neutrophils. Hypertension 43(6), 1246–1251 (2004).
  Medline CASGoogle Scholar
• 30 Shimo-Nakanishi Y, Hasebe T, Suzuki A et al. Functional effects of NAD(P)H oxidase p22(phox) C242T mutation in human leukocytes and association with thrombotic cerebral infarction. Atherosclerosis 175(1), 109–115 (2004).
  Medline CASGoogle Scholar
• 31 Fang S, Wang L, Jia C. Association of p22phox gene C242T polymorphism with coronary artery disease: a meta-analysis. Thromb. Res. 125(5), e197–201 (2010).
  Medline CASGoogle Scholar
• 32 Jaquet V, Scapozza L, Clark RA, Krause KH, Lambeth JD. Small-molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. Antioxid. Redox Signal. 11(10), 2535–2552 (2009).
  Medline CASGoogle Scholar